SCHEMBL23405471

SCHEMBL23405471

Oc1ccc(-c2cn(-c3ccc(O)c(F)c3F)nn2)cc1O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SNCA P37840 3/20 0.62
▸ MAPT P10636 2/20 0.62
▸ FLT3 P36888 1/20 0.42
▸ ESRRG P62508 1/20 0.41
▸ HSD17B1 P14061 2/20 0.40
▸ HSD17B2 P37059 2/20 0.40
▸ MIF P14174 2/20 0.38
▸ CA1 P00915 4/20 0.38
▸ CA2 P00918 4/20 0.38
▸ CA5A P35218 2/20 0.38
▸ CA5B Q9Y2D0 2/20 0.38
▸ CA12 O43570 2/20 0.37
▸ CA9 Q16790 2/20 0.37
▸ GFER P55789 2/20 0.37
▸ GAA P10253 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ PTGS2 P35354 1/20 0.36
▸ STS P08842 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23405493 0.83 SNCA (0.59) SNCAMAPTFLT3ESRRGHSD17B1
SCHEMBL23405500 0.82 SNCA (0.61) SNCAMAPTFLT3ESRRGHSD17B1
SCHEMBL23405489 0.78 MAPT (0.78) SNCAMAPTFLT3HSD17B1HSD17B2
SCHEMBL12682333 0.77 SNCA (1.00) SNCAMAPTFLT3ESRRGHSD17B1
SCHEMBL23405494 0.77 MAPT (0.81) SNCAMAPTFLT3HSD17B1HSD17B2
SCHEMBL23405482 0.76 MAPT (0.83) SNCAMAPTFLT3ESRRGHSD17B1
SCHEMBL23405479 0.76 MAPT (0.78) SNCAMAPTFLT3HSD17B1HSD17B2
SCHEMBL23557576 0.75 MIF (0.50) SNCAMAPTFLT3HSD17B1HSD17B2
SCHEMBL23405505 0.75 MAPT (0.72) SNCAMAPTFLT3HSD17B1HSD17B2
SCHEMBL23405495 0.75 MAPT (0.82) SNCAMAPTFLT3ESRRGHSD17B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12297178-B2 Triazole derivative and use thereof GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2025-05-13 — — US claimed
US-20240166611-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2024-05-23 — — US claimed
US-20210163425-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2021-06-03 — — US claimed
US-12297178-B2 Triazole derivative and use thereof GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2025-05-13 — — US disclosed
US-20240166611-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2024-05-23 — — US disclosed
US-20210163425-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2021-06-03 — — US disclosed
US-20210163425-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2021-06-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210163425-A1 TRIAZOLE DERIVATIVE AND USE THEREOF FABP4, LIPC, GPR119 SNCA 4775/4885MAPT 2951/4885FLT3 386/4885
US-12297178-B2 Triazole derivative and use thereof FABP4, LIPC, GPR119 SNCA 4771/4885MAPT 2945/4885FLT3 430/4885
US-20240166611-A1 TRIAZOLE DERIVATIVE AND USE THEREOF FABP4, LIPC, GPR119 SNCA 4771/4885MAPT 2945/4885FLT3 430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback